ArticleFish physiology and biochemistry2025
Remediation of hypoxia induced brain alteration with pyrimidine treatment in the freshwater catfish, Heteropneustes fossilis.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low dissolved oxygen (DO), or hypoxia, has a profound impact on the physiological and neurological health of aquatic organisms, particularly oxygen-sensitive organs such as the brain. The aim was to investigate the effects of pyrimidine and its derivative, arylvinylpyrimidine (AVP), on neuronal health in the brain of the lesser studied Heteropneustes fossilis under hypoxic conditions. Laboratory-acclimatized fish were exposed to critical threshold hypoxia (2 mg/L DO for 8 h) based on behavioural and brain histopathology observations. For remediation by pyrimidine and AVP in the hypoxic brain, fish were divided into eight experimental groups; four groups maintained for five days as control [without treatment, with 8 h hypoxia, and only drug effect (pyrimidine, 10 pg/mL or AVP, 0.1 µg/mL)] and four groups were maintained as pre- (drug for five days followed by hypoxia for 8 h) and post- (8 h hypoxia followed by drug for five days) treatment with pyrimidine (10 pg/mL) and AVP (0.1 µg/mL) separately. The results showed that air breather H. fossilis exhibited severe hypoxic effects on neuronal health. Hypoxia significantly elevated antioxidant enzyme activity, and lipid peroxidation (LPO), reduced carbohydrate concentration, and increased total lipid content without affecting total protein level in the brain. The hypoxic brain showed a clear stress effect on cellular and neuronal texture. Hypoxia also significantly influenced neurotransmitter synthesis enzymes [acetylcholinesterase (AChE), tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), and tryptophan hydroxylase-2 (TPH2)]. Hypoxia induced brain alteration was effectively reversed by pyrimidine and AVP treatment. Among different experimental sets, post-treatment being more effective than pre-treatment, and AVP showed greater effectiveness than pyrimidine. These findings demonstrate pyrimidine and AVP as neuroprotective agents against hypoxia-induced damage in the H. fossilis brain and suggest their potential therapeutic utility in managing hypoxia induced neuronal damage in aquatic animals.
Indexed as
Identifiers
41428268What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.